
epkinly[™]
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg | 48mg

A care partner's guide to EPKINLY



Actor portrayals.

What is EPKINLY?

EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma that has come back or that did not respond to previous treatment after receiving 2 or more treatments. EPKINLY is approved based on patient response data. A study is ongoing to confirm the clinical benefit of EPKINLY. It is not known if EPKINLY is safe and effective in children.

SELECT IMPORTANT SAFETY INFORMATION

EPKINLY can cause serious side effects, including:

- **Cytokine release syndrome (CRS)**, which is common during treatment with EPKINLY and can be serious or life-threatening.
- **Neurologic problems** that can be life-threatening and lead to death.
- **Infections and low blood cell counts.**


Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 11-12. Please see [Medication Guide](https://www.epkinly.com/medguide) at [EPKINLYMedGuide.com](https://www.epkinly.com/medguide).

Table of Contents

Your Role as a Care Partner	4
Caring for a loved one with DLBCL.....	4
Learn About EPKINLY	5
How EPKINLY works	5
Results with EPKINLY.....	7
How EPKINLY injections are given.....	9
Important Safety Information.....	11
Support for You and Your Loved One	13
Supporting your loved one	13
Discussing EPKINLY as a treatment option.....	14
EPKINLY Treatment Tracker.....	15
Appointment calendar.....	17
Communicating with your loved one.....	21
Taking care of yourself.....	22
Resources and support.....	23
Important contact information.....	25

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 11-12. Please see [Medication Guide](#) at [EPKINLYMedGuide.com](#).





Supporting someone you love

You've been there for your loved one every step of the way and have seen firsthand the impact of diffuse large B-cell lymphoma (DLBCL). As a care partner, you offer unique support and are an integral part of your loved one's healthcare team. This role can be physically and emotionally demanding, so we are dedicated to helping you find ways to support yourself while caring for your loved one throughout treatment with EPKINLY.

These are some of the roles you may need to take on during your loved one's treatment:

- **Medical:** Helping with treatment decisions, scheduling appointments, and monitoring side effects
- **Logistical:** Managing their insurance, driving them to appointments, and running errands to give them more time to focus on achieving remission
- **Emotional:** Encouraging them to share their feelings and helping with treatment decisions so they feel supported

In this brochure, you'll find helpful information and resources that can support you in your role as a care partner.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 11-12. Please see [Medication Guide](#) at [EPKINLYMedGuide.com](#).


epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/148mg

Caring for a loved one with DLBCL

Someone you love may have been diagnosed with DLBCL and found out that their cancer returned or didn't respond to treatment. But remission is still possible, and there is another option.

EPKINLY is a different kind of treatment for certain types of DLBCL that returned or didn't respond after 2 or more prior treatments. It is the first-and-only bispecific antibody treatment for DLBCL that is given as a subcutaneous injection, which means it's given under the skin.

EPKINLY is not chemotherapy or an infusion. It is given as an injection when your loved one needs to start treatment. Learn more about EPKINLY and see if it could be the right treatment for them.



Visit [EPKINLY.com](https://www.epkinly.com) to learn more about EPKINLY.



SELECT IMPORTANT SAFETY INFORMATION

EPKINLY can cause serious side effects including cytokine release syndrome (CRS), neurologic problems, infections, and low blood cell counts.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 11-12. Please see [Medication Guide](#) at [EPKINLYMedGuide.com](https://www.epkinly.com/medguide).


epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/148mg

EPKINLY harnesses the power of the immune system

EPKINLY is the first-of-its-kind bispecific antibody treatment for certain types of DLBCL that returned or didn't respond after 2 or more prior treatments

EPKINLY is different from chemotherapy or stem cell therapy. It is a bispecific antibody that works by harnessing the power of the immune system to fight cancer.

EPKINLY is designed to target 2 types of cells in the body—T cells and B cells.

- T cells are immune cells that fight infections, as well as cancer cells
- B cells are another type of immune cell, and in DLBCL, some B cells can become cancerous and grow uncontrollably


EPKINLY works by attaching to both T cells and B cells, binding them together so that the T cells can attack and destroy B cells.

SELECT IMPORTANT SAFETY INFORMATION

Because EPKINLY works with your immune system it **can cause serious side effects, including cytokine release syndrome (CRS), neurologic problems, infections, and low blood cell counts.**

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 11-12. Please see [Medication Guide](#) at [EPKINLYMedGuide.com](#).

epkinly™
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/148mg



SELECT IMPORTANT SAFETY INFORMATION

Because EPKINLY works with your immune system it **can cause serious side effects, including cytokine release syndrome (CRS), neurologic problems, infections, and low blood cell counts.**

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 11-12. Please see [Medication Guide](#) at EPKINLYMedGuide.com.



Remission is possible

EPKINLY delivers powerful efficacy that can transform uncertainty into hope

The goal of EPKINLY is to help patients achieve long-term remission. Learn about the results that were seen in the clinical study with EPKINLY.

EPKINLY is approved based on patient response data. A study is ongoing to confirm the clinical benefit of EPKINLY.

61%

Complete or partial remission

EPKINLY helped 61% of patients (90 of 148) achieve complete or partial remission (signs of cancer either disappeared or decreased)

38%

Complete remission

EPKINLY helped 38% of patients (56 of 148) achieve complete remission (signs of cancer disappeared completely)

23%

Partial remission

EPKINLY helped 23% of patients (34 of 148) achieve partial remission (signs of cancer decreased)

15.6 months

Of the 90 patients who achieved complete or partial remission, half were **still responding to EPKINLY** for at least 15.6 months

SELECT IMPORTANT SAFETY INFORMATION

Important Warnings—EPKINLY can cause serious side effects, including:

- **Cytokine release syndrome (CRS)**, which is common during treatment with EPKINLY and can be serious or life-threatening. To help reduce your risk of CRS, you may receive other medicines before receiving EPKINLY and you will also be given smaller doses of EPKINLY for the first 2 doses (called “step-up” dosing). Your first full dose will be given on day 15 of your first cycle of treatment and you should be hospitalized for 24 hours after due to risk of CRS and neurologic problems. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule.
- **Neurologic problems** that can be life-threatening and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 11-12. Please see [Medication Guide](#) at [EPKINLYMedGuide.com](#).


epkinly™
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/148mg



Patients who achieved complete or partial remission **started seeing results in as little as 6 weeks** on treatment with EPKINLY.*

*Median of 1.4 months. Range 1 to 8.4 months.

How was EPKINLY studied?

EPKINLY was studied in 148 patients with DLBCL who had 2 or more treatments and whose cancer returned or didn't respond.

Patients had been through a median[†] of 3 different types of treatments (range of prior treatments was 2 to 11), such as chemotherapy, immunotherapy (uses your body's immune system to help fight cancer), stem cell transplant, and CAR T (chimeric antigen receptor T cell) therapy.

[†]The median is the number that is exactly in the middle of range seen in the study.

SELECT IMPORTANT SAFETY INFORMATION

Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. **These may be symptoms of CRS or neurologic problems. Do not** drive or use heavy machinery or do other dangerous activities if you have any symptoms that impair consciousness until your symptoms go away.

Your healthcare provider will monitor you for symptoms of CRS, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 11-12. Please see [Medication Guide](#) at [EPKINLYMedGuide.com](#).


epkinly[™]
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/148mg

Unlike an infusion that may take time to administer, EPKINLY is given as an injection

Your loved one may receive treatment at a nearby outpatient center that is able to administer EPKINLY

EPKINLY dosing schedule



EPKINLY uses a “step-up dosing schedule.” During the first 2 weeks of treatment, your loved one will receive smaller “step-up” doses than the doses they will receive in week 3 and for the rest of their treatment.

Important things to know:

- If a dose of EPKINLY is delayed for any reason, they may need to repeat the step-up dosing schedule
- The step-up dosing schedule is designed to increase tolerability and help limit the potential for, and severity of, CRS
- The healthcare provider will discuss with them the need to be hospitalized for 24 hours after their first full dose of EPKINLY (week 3/3rd dose) due to the risk of CRS and neurologic problems
- Your loved one may have side effects during treatment. The healthcare provider will monitor them for symptoms of CRS, neurologic problems, infections and low blood cell counts during treatment with EPKINLY. The healthcare provider may temporarily stop or completely stop treatment with EPKINLY if your loved one develops certain side effects
- Before each dose of EPKINLY in the first 4 weeks of treatment, they will receive other medicines to help reduce the risk of CRS. The healthcare provider will decide if they need to receive medicine to help reduce the risk of CRS in later doses of EPKINLY

SELECT IMPORTANT SAFETY INFORMATION

EPKINLY can cause other serious side effects, including:

- **Infections** that may lead to death. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, or feeling weak or generally unwell.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 11-12. Please see [Medication Guide](#) at [EPKINLYMedGuide.com](#).



Staying on treatment with EPKINLY may help your loved one achieve remission and continue to see response

Ongoing treatment with EPKINLY ensures that the medicine continues to work in the body to help maintain remission.

- Patients will receive EPKINLY for as long as their healthcare provider finds it is working for them and their side effects are manageable
- Your loved one's healthcare provider may delay or completely stop treatment with EPKINLY if certain side effects are experienced



SELECT IMPORTANT SAFETY INFORMATION

EPKINLY may cause other serious side effects, including:

- **Low blood cell counts** are common during treatment with EPKINLY and can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including low white blood cells (neutropenia), which can increase your risk for infection; low red blood cells (anemia), which can cause tiredness and shortness of breath; and low platelets (thrombocytopenia), which can cause bruising or bleeding problems.

Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 11-12. Please see [Medication Guide](#) at [EPKINLYMedGuide.com](#).



Keep track of your loved one's injections and how they're feeling in the [Treatment Tracker](#) on page 15.

Important Safety Information

What is EPKINLY?

EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma that has come back or that did not respond to previous treatment after receiving 2 or more treatments. EPKINLY is approved based on patient response data. A study is ongoing to confirm the clinical benefit of EPKINLY. It is not known if EPKINLY is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Important Warnings—EPKINLY can cause serious side effects, including:

- **Cytokine release syndrome (CRS)**, which is common during treatment with EPKINLY and can be serious or life-threatening. To help reduce your risk of CRS, you may receive other medicines before receiving EPKINLY and you will also be given smaller doses of EPKINLY for the first 2 doses (called “step-up” dosing). Your first full dose of EPKINLY will be given on day 15 of your first cycle of treatment and you should be hospitalized for 24 hours after due to risk of CRS and neurologic problems. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule.
- **Neurologic problems** that can be life-threatening and lead to death. Neurologic problems may happen days or weeks after you receive EPKINLY.

Tell your healthcare provider or get medical help right away if you develop a fever of 100.4°F (38°C) or higher; dizziness or lightheadedness; trouble breathing; chills; fast heartbeat; feeling anxious; headache; confusion; shaking (tremors); problems with balance and movement, such as

trouble walking; trouble speaking or writing; confusion and disorientation; drowsiness, tiredness or lack of energy; muscle weakness; seizures; or memory loss. **These may be symptoms of CRS or neurologic problems. Do not** drive or use heavy machinery or do other dangerous activities if you have any symptoms that impair consciousness until your symptoms go away.

EPKINLY can cause other serious side effects, including:

- **Infections** that may lead to death. Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4°F (38°C) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, or feeling weak or generally unwell.
- **Low blood cell counts** are common during treatment with EPKINLY and can be serious or severe. Your healthcare provider will check your blood cell counts during treatment. EPKINLY may cause low blood cell counts, including low white blood cells (neutropenia), which can increase your risk for infection; low red blood cells (anemia), which can cause tiredness and shortness of breath; and low platelets (thrombocytopenia), which can cause bruising or bleeding problems.

Your healthcare provider will monitor you for symptoms of CRS, neurologic problems, infections, and low blood cell counts during treatment with EPKINLY. Your healthcare provider may temporarily stop or completely stop treatment with EPKINLY if you develop certain side effects.

Please see additional Important Safety Information on page 12. Please see [Medication Guide](#), including Important Warnings at [EPKINLYMedGuide.com](#).

epkinly™
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/148mg

Important Safety Information (continued)

Before you receive EPKINLY, tell your healthcare provider about all your medical conditions, including if you have an infection, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. If you receive EPKINLY while pregnant, it may harm your unborn baby. **If you are a female who can become pregnant**, your healthcare provider should do a pregnancy test before you start treatment with EPKINLY and you should use effective birth control (contraception) during treatment and for 4 months after your last dose of EPKINLY. Tell your healthcare provider if you become pregnant or think that you may be pregnant during treatment with EPKINLY. Do not breastfeed during treatment with EPKINLY and for 4 months after your last dose of EPKINLY.

The most common side effects of EPKINLY include CRS, tiredness, muscle and bone pain, injection site reactions, fever, stomach-area (abdominal) pain, nausea, and diarrhea. These are not all the possible side effects of EPKINLY. Call your doctor for medical advice about side effects.

You are encouraged to report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to Genmab US, Inc. at 1-855-4GENMAB (1-855-443-6622).

Please see additional Important Safety Information, including Important Warnings for CRS and neurologic problems, on page 11. Please see the Medication Guide, including Important Warnings at EPKINLYMedGuide.com.



Supporting your loved one

As a care partner, you help advocate for your loved one; you work with the healthcare team to decide on a treatment plan and help your loved one through the treatment process. Here are some suggestions you may find beneficial:



Before Appointments

Preparing for treatment can be stressful, but you can help by knowing your loved one's medical history before going to appointments.




During Appointments

You can help at appointments by coming prepared with questions, taking notes during the conversation, and keeping track of upcoming appointments.



After Appointments

After appointments with the healthcare team, it's important to monitor your loved one for any side effects they may have.



Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 11-12. Please see [Medication Guide](#) at [EPKINLYMedGuide.com](#).

epkinly[™]
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/148mg

Discussing EPKINLY as a treatment option

To decide if EPKINLY could be the right treatment option for your loved one, use this guide to prepare any questions you may have for the healthcare provider.

Previous Treatments

Check all previous DLBCL treatments.

- CAR T therapy
- Chemoimmunotherapy (eg, R-CHOP)
- Stem cell transplant
- Other _____

Current Medications

List all current medications, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Treatment Goals

What goals do you and your loved one have for treatment?
Write down any treatment goals and share them with the healthcare provider.

Questions About EPKINLY

- How is EPKINLY different from other treatments?
- Is remission possible with EPKINLY?
- How will EPKINLY be given?

R-CHOP=rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 11-12. Please see [Medication Guide](#) at [EPKINLYMedGuide.com](#).



EPKINLY Treatment Tracker

If your loved one has just started treatment or is currently on EPKINLY, it's important to keep track of how they're feeling and what they may be experiencing in between appointments. Be sure to discuss these with your loved one's healthcare provider.

DOSE 1 Date: / /

How they're feeling after treatment: _____

Next appointment date: _____

Questions for the healthcare team: _____

DOSE 2 Date: / /

How they're feeling after treatment: _____

Next appointment date: _____

Questions for the healthcare team: _____

DOSE 3 Date: / /

How they're feeling after treatment: _____

Next appointment date: _____

Questions for the healthcare team: _____

DOSE 4 Date: / /

How they're feeling after treatment: _____

Next appointment date: _____

Questions for the healthcare team: _____

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 11-12. Please see [Medication Guide](#) at [EPKINLYMedGuide.com](#).



EPKINLY Treatment Tracker

DOSE 5 Date: / /

How they're feeling after treatment: _____

Next appointment date: _____

Questions for the healthcare team: _____

DOSE 6 Date: / /

How they're feeling after treatment: _____

Next appointment date: _____

Questions for the healthcare team: _____

DOSE 7 Date: / /

How they're feeling after treatment: _____

Next appointment date: _____

Questions for the healthcare team: _____

This tracker helps you track the first 7 doses of EPKINLY. Please continue to track for as long as your loved one receives the treatment. Call the healthcare provider for medical advice about any side effects that your loved one is experiencing.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 11-12. Please see [Medication Guide](#) at [EPKINLYMedGuide.com](#).



Appointment calendar

Use this calendar to keep track of your loved one's appointments, including injections and tests. Make notes here prior to the appointment if you have questions for the healthcare provider.

MONTH:

SUN	MON	TUE	WED	THU	FRI	SAT

Notes

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 11-12. Please see [Medication Guide](#) at [EPKINLYMedGuide.com](#).



Appointment calendar

MONTH:

SUN	MON	TUE	WED	THU	FRI	SAT

Notes

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 11-12. Please see [Medication Guide](#) at [EPKINLYMedGuide.com](#).



Appointment calendar

MONTH:

SUN	MON	TUE	WED	THU	FRI	SAT

Notes

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 11-12. Please see [Medication Guide](#) at [EPKINLYMedGuide.com](#).



Appointment calendar

MONTH:

SUN	MON	TUE	WED	THU	FRI	SAT

Notes

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 11-12. Please see [Medication Guide](#) at [EPKINLYMedGuide.com](#).



Communicating with your loved one

When someone you love is going through treatment, it's easy to deprioritize your own needs. Having honest conversations about how you're feeling, how you can provide support, and what you need in order to avoid burnout can strengthen a relationship and help you provide the best care possible.

Consider these tips and keep them in mind:

- Be available to talk, but don't force anything
- Remember that people communicate in different ways
- Take cues from the person you're caring for
- Be flexible about what you hope to discuss and where you can find agreement
- Respect your loved one's privacy or their need to be alone

Care partner & patient discussion guide

It's important that care partners and their loved ones are on the same page and are able to express their needs. Use these statements to help guide you when you are talking with your loved one about their treatment.

When you say _____, it makes me feel _____.

If I am feeling _____, how can we work through that together?

If we need more support, we can bring in _____ as an additional care partner.

I can _____ to best respect your independence during treatment.

The best time to check in with me about how I'm feeling is _____.

During stressful times, I can _____ to make things easier for both of us.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 11-12. Please see [Medication Guide](#) at [EPKINLYMedGuide.com](#).



MyNavCare™ provides personalized support to help patients get started and stay on treatment with EPKINLY



With *MyNavCare*, you can receive personalized support throughout the treatment journey from a dedicated team that cares.



A partner on the treatment journey

Your loved one's healthcare provider is your main source for treatment information. With *MyNavCare*, you gain access to additional resources and medication information.

- Dedicated support throughout your loved one's treatment
- Information about treatment access and financial support*
- Insight into independent organizations that may provide additional assistance
- Additional tools and resources that may help along the way



Financial assistance for eligible patients

MyNavCare may be able to help uninsured or underinsured patients receive financial assistance and information. This includes:

- Co-pay assistance program for commercially insured patients*
- Independent patient assistant foundation information†
- Genmab Patient Assistance Program



Ongoing personalized support

The **Patient Engagement Liaison** is an experienced nurse and trained in treatment support.‡ They're dedicated to you and your care partner, helping to:

- Provide information about your condition
- Connect you to external organizations
- Offer resources for patients and care partners

*Based on eligibility requirements and Terms and Conditions.

†Eligibility criteria is determined by each independent third-party foundation. *MyNavCare* does not determine eligibility and cannot guarantee foundations will offer assistance.

‡Patient Engagement Liaisons are provided by *MyNavCare* Patient Support and do not work under the direction of your doctor or provide medical advice. Patients should speak with their doctor about any treatment-related questions.

Contact a **MyNavCare** Support Specialist by calling **1-866-NAV-CAR1** (1-866-628-2271), Monday-Friday, 8 AM-8 PM ET. Or visit [MyNavCare.com](https://www.mynavcare.com) to learn more.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 11-12. Please see [Medication Guide](https://www.epkinlymedguide.com) at [EPKINLYMedGuide.com](https://www.epkinlymedguide.com).

Additional resources

There are many other resources and tools that can provide support. Here are some organizations that can help you connect with others who are going through similar experiences, as well as provide information and tips throughout treatment:



The Leukemia & Lymphoma Society

www.lls.org
800-955-4572



CancerCare

www.cancercare.org
800-813-HOPE (4673)



Lymphoma Research Foundation

www.lymphoma.org
800-500-9976



Family Reach

www.familyreach.org
973-394-1411 ext. 1



American Cancer Society

www.cancer.org
800-227-2345



Patient Advocate Foundation

www.patientadvocate.org
800-532-5274

There are many available resources that may be helpful to patients, families, and care partners dealing with cancer. The above resources are not controlled, owned, or endorsed by Genmab/AbbVie, and Genmab/AbbVie is not responsible for their content.



Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 11-12. Please see [Medication Guide](#) at EPKINLYMedGuide.com.



Important contact information

Use this space to take note of your loved one's healthcare information, as well as contact information for their doctors, pharmacy, and backup care partners.

Doctor

Name: _____

Phone Number: _____

Office Address: _____

Nurse

Name: _____

Phone Number: _____

Office Address: _____

Pharmacy

Name: _____

Phone Number: _____

Pharmacy Address: _____

Backup Care Partner

Name: _____

Phone Number: _____

Other Contacts

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 11-12. Please see [Medication Guide](#) at [EPKINLYMedGuide.com](#).



A care partner's guide to EPKINLY

Visit [EPKINLY.com](https://epkinly.com) for more information.

Please see Important Safety Information, including Important Warnings for CRS and neurologic problems, on pages 11-12. Please see [Medication Guide at EPKINLYMedGuide.com](https://epkinlymedguide.com).



Distributed and marketed by Genmab US, Inc. 777 Scudders Mill Road, Plainsboro, NJ 08536.

Distributed and marketed by AbbVie Inc. 1 North Waukegan Road, North Chicago, IL 60064.

EPKINLY and *MyNavCare* are trademarks of Genmab A/S. All other trademarks and registered trademarks are the property of their respective owners.

©2023 Genmab A/S and AbbVie. All rights reserved.

12/2023 COM-US-EPK-0000419

The epkinly logo features the word "epkinly" in a bold, dark blue sans-serif font. Above the letter "i" is a stylized circular graphic composed of overlapping teal and purple segments. Below "epkinly" is the text "epcoritamab-bysp" in a smaller, dark blue sans-serif font, followed by "SUBCUTANEOUS INJECTION 4mg/48mg" in an even smaller, dark blue sans-serif font.

epkinly[™]
epcoritamab-bysp
SUBCUTANEOUS INJECTION 4mg/48mg